Imed Helal, MD, PhD, FISN
Riyadh – KSA, Saudi Arabia
Dr Imed HELAL is a faculty member of the Nephrology Department, Charles Nicolle Hospital and Clinical Professor at university of Tunis Almanar, Tunisia. He received his medical degree from the University of Monastir, he start his renal fellowship at Department of Nephrology (M8) Charles Nicolle Hospital (Tunis-Tunisia) and completed his nephrology specialisation and his MD at Necker Hospital in Paris – France. He carried out a research fellowship and post-doc research on progression factors of autosomal dominant polycystic kidney disease at the Nephrology Department of the UC health University of Colorado Hospital (UCH), Denver, USA. Professor Helal has authored or co-authored articles in the clinical Journal of American Society of nephrology, Nature Reviews Nephrology, American Journal of Nephrology, American Journal of Medicine, Kidney International reports, and other international journals. He has also contributed chapters to key nephrology textbooks such as Schrier’s disease of The Kidney, has peer-reviewed articles for several international and national journals, served as associate editor at BMC nephrology and general secretary of Tunisian society of Nephrology. Professor Helal’s principal clinical activity and research interests include ADPKD, CKD, early diagnosis of CKD, pregnancy in dialysis, recovery of kidney function and acute kidney injury. Dr Helal had received the first Prize of International Society of Nephrology poster Award during the World Congress Of Nephrology (Canada, 2011) and Research contribution award for the year 2019 from Diaverum AB.
His research interests keywords: ADPKD, AKI, CKD, Pregnancy in dialysis.
Honors & Awards
• 1st Prize of International Society of Nephrology poster Award, World Congress Of Nephrology, Vancouver, Canada, 8-12 April 2011
• Research contribution award for the year 2019 from Diaverum AB
1. Hamida FB, Barbouch S, Bardi R, et al. Acute rejection episodes after kidney transplantation. Saudi J Kidney Dis Transpl. 2009; 20(3): 370-374.
2. Helal I, Byzun A, Rerolle JP, Morelon E, Kreis H, Bruneel-Mamzer MF. Acute renal failure following allogeneic hematopoietic cell transplantation: Incidence, outcome and risk factors. Saudi J Kidney Dis Transpl. 2011; 22(3): 437-443.
3. Helal I, Gorsane I, Harzallah A, et al. Approach of hypertension in autosomal dominant polycystic kidney disease. Ann Clin Exp Hypertension. 2013; 1(1): 1002.
4. Helal I. Autosomal dominant polycystic kidney disease: New insights into treatment. Saudi J Kidney Dis Transpl. 2013; 24(2): 230-234.
5. Helal I, Smaoui W, Hamida FB, et al. Cardiovascular risk factors in hemodialysis and peritoneal dialysis patients. Saudi J Kidney Dis Transpl. 2010; 21(1): 59-62.
6. Helal I, McFann K, Reed B, Yan XD, Schrier RW. Changing referral characteristics of patients with autosomal dominant polycystic kidney disease. Am J Med. 2013; 126(9): 832.e7-832.e11. doi: 10.1016/j.amjmed.2012.12.018
7. Helal I, Lassoued F, Maiz HB, Kheder A. Clinical presentation and outcomes of autosomal dominant polycystic kidney disease in the elderly. AJMSM. 2013; 1(1): doi: 10.12691/ajmsm-1-1-3
8. Helal I, Belhadj R, Mohseni A, et al. Clinical significance of N-terminal Pro-B-type natriuretic peptide (NT-proBNP) in hemodialysis patients. Saudi J Kidney Dis Transpl. 2010; 21(2): 262-268.
9. Helal I, Belhadj R, Mohseni A, et al. Comparison of C-reactive protein and high-sensitivity C-reactive protein levels in patients on hemodialysis. Saudi J Kidney Dis Transpl. 2012; 23(3): 477-483.
10. Gorsane I, Helal I, Yacoub I, Hamida FB, Abderrahim E, Abdallah TB. Cyclosporine therapy in steroid-dependent or steroid-resistant idiopathic focal and segmental glomerulosclerosis. Saudi J Kidney Dis Transpl. 2016; 27(5): 958-965. doi: 10.4103/1319
11. Hamida FB, Fatma LB, Barbouch S, et al. Effect of sevelamer on mineral and lipid abnormalities in hemodialysis patients. Saudi J Kidney Dis Transpl. 2008; 19(2): 183-188.
12. Helal I, Elkateb H, Hedri H, Hajri M, Hamida FB. Efficacy and safety of calcium acetate-magnesium carbonate in the treatment of hyperphosphatemia in dialysis patients. Saudi J Kidney Dis Transpl. 2016; 27(6): 1162-1167.
13. Helal I, Reed B, Schrier RW. Emergent early markers of renal progression in autosomal-dominant polycystic kidney disease patients: Implications for prevention and treatment. Am J Nephrol. 2012; 36(2): 162-167. doi: 10.1159/000341263
14. Gorsane I, Amri N, Younsi F, Helal I, Kheder A. Erectile dysfunction in hemodialysis patients. Saudi J Kidney Dis Transpl. 2016; 27(1): 23-28. doi: 10.4103/1319-2442.174057
15. Helal I, Elyounsi F, Hamida FB, et al. Fracture and embolization of a temporary hemodialysis femoral catheter. J Vasc Access. 2010; 11(1): 74-75.
16. Helal I, Reed B, McFann K, et al. Glomerular hyperfiltration and renal progression in children with autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2011; 6(10): 2439-2443. doi: 10.2215/CJN.01010211
17. Helal I, Fick-Brosnahan GM, Reed-Gitomer B, Schrier RW. Glomerular hyperfiltration: Definitions, mechanisms and clinical implications. Nat Rev Nephrol. 2012; 8(5): 293-300. doi: 10.1038/nrneph.2012.19
18. Letavernier E, Bruneval P, Mandet C, et al. High sirolimus levels may induce focal segmental glomerulosclerosis de novo. Clin J Am Soc Nephrol. 2007; 2(2): 326-333.
19. Helal I, Gorsane I, Hamida FB, Kheder JA. Impact of dialysis modality on kidney transplantation outcomes. Biomedical Science and Engineering. 2015; 8: 67-72.
20. Helal I, Abderrahim E, Ben Hamida F, et al. Impact of dialysis modality on posttransplantation results in kidney transplantation. Transplant Proc. 2007; 39(8): 2547-2549. doi: 10.1016/j.transproceed.2007.08.017
21. Gorsane I, Mahfoudhi M, Helal I, Abdallah TB. Indications and results of kidney biopsies in patients over 65 years old. Open Journal of Nephrology. 2015; 5: 49-53.
22. Helal I, Bahlous A, El Younsi F, et al. Interest of bone alkaline phosphatase in hemodialysis patients. Tunis Med. 2008; 86(5): 427-430.
23. Derouiche A, Mechri M, Ktari MM, Helal I, Ben Abdallah T, Chebil M. Lymphoceles after renal transplantation: Study of risk factors. Prog Urol. 2010; 20(4): 301-306. doi: 10.1016/j.purol.2009.05.003
24. Abderrahim E, Harzallah A, Barbouch S, et al. Lymphoproliferative disorders in kidney transplant recipients: Incidence, clinical characteristics and outcome. Rev Med.
25. Helal I, Goucha R, Karoui C, et al. Nodular glomerulosclerosis in patients’ without history of diabetes mellitus: a case report. Cases J. 2009; 2: 6792. doi: 10.4076/1757-1626-2-6792
26. Ben Hamida F, Ben Abdallah T, Goucha R, et al. Outcome of living unrelated (commercial) renal transplantation: Report of 20 cases. Transplant Proc. 2001; 33(5): 2660-2661.
27. Rerolle JP, Helal I, Morelon E. Parvovirus B19 infection after renal transplantation. Nephrologie. 2003; 24(6): 309-315.
28. Rerolle JP, Morelon E, Helal I, et al. Parvovirus B19-related anaemia after renal transplantation. Scand J Infect Dis. 2004; 36(6-7): 513-516.
29. Gorsane I, Mahfoudhi M, Younsi F, Helal I, Abdallah TB. Prevalence and risk factors of hypertension in hemodialysis. Open Journal of Nephrology. 2015; 5: 54-60.
30. Helal I, Reed B, Mettler P, et al. Prevalence of cardiovascular events in patients with autosomal dominant polycystic kidney disease. Am J Nephrol. 2012; 36(4): 362-370. doi: 10.1159/000343281
31. Helal I, Goucha R, Hamida FB, Elyounsi F, Maiz HB, Kheder A. Renal AA amyloidosis in a patient with hereditary complete complement C4 deficiency. Saudi J Kidney Dis Transpl. 2011; 22(5): 1008-1011.
32. Gorsane I, Mahfoudhi M, Ounissi M, Younsi F, Helal I, Abdallah TB. Renal replacement therapy in patients over 65 years old. Open Journal of Nephrology. 2015; 5: 44-48.
33. Hamida F, Gorsane I, Gharbi C, et al. Renal manifestations in tuberous sclerosis. Rev Med Interne. 2006; 27(11): 836-842.
34. Tkachenko O, Helal I, Shchekochikhin D, Schrier RW. Renin-Angiotensin-aldosterone system in autosomal dominant polycystic kidney disease. Curr Hypertens Rev. 2013; 9(1): 12-20.
35. Helal I, Handous I, Khadhar M, et al. Ruptured intracranial aneurysm and recessive polycystic kidney disease: A rare association. Saudi J Kidney Dis Transpl. 2019; 30(4): 982-984. doi: 10.4103/1319-2442.265479
36. Helal I, McFann K, Reed B, Yan XD, Schrier RW, Fick-Brosnahan GM. Serum uric acid, kidney volume and progression in autosomal-dominant polycystic kidney disease. Nephrol Dial Transplant. 2013; 28(2): 380-385. doi: 10.1093/ndt/gfs417
37. Helal I, Abdallah TB, Ounissi M, et al. Short- and long-term outcomes of kidney donors: A report from Tunisia. Saudi J Kidney Dis Transpl. 2012; 23: 853-859. doi: 10.4103/1319-2442.98187
38. Cherif M, Ounissi M, Karoui C, et al. Short- and long-term outcomes of living donors in Tunisia: a retrospective study. Transplant Proc. 2010; 42(10): 4311-4313. doi: 10.1016/j.transproceed.2010.09.119
39. Helal I, Chan L. Steroid and calcineurin inhibitor-sparing protocols in kidney transplantation. Transplant Proc. 2011; 43(2): 472-477. doi: 10.1016/j.transproceed.2011.01.054
40. Helal I, Abderrahim E, Ben Hamida F, et al. The first year renal function as a predictor of long-term graft survival after kidney transplantation. Transplantation Proceedings. 2009; 41(2): 648-650. doi: 10.1016/j.transproceed.2009.02.036
41. Reed B, Helal I, McFann K, Wang W, Yan XD, Schrier RW. The impact of type II diabetes mellitus in patients with autosomal dominant polycystic kidney disease. Nephrol Dial Transplant. 2012; 27(7): 2862-2865. doi: 10.1093/ndt/gfr744
42. Helal I, Kaaroud H, Goucha R, Ben Moussa F, Ben Maiz H, Kheder A. The pattern of histologically-proven acute post-infectious glomerulonephritis in Tunisian adults seen in 1976-2004. Arab J Nephrol Transplant. 2012; 5(2): 93-96.
43. Abdallah TB, Ounissi M, Cherif M, et al. The role of generics in kidney transplant: mycophenolate mofetil 500 versus mycophenolate: 2-year results. Exp Clin Transplant. 2010; 8(4): 292-296.
44. Barbouch S, Hajji M, Helal I, et al. Tuberculosis after renal transplant. Exp Clin Transplant. 2017; 15(Suppl 1): 200-203.
45. Helal I, Al-Rowaie F, Abderrahim E, Kheder A. Update on pathogenesis, management, and treatment of hypertension in autosomal dominant polycystic kidney disease. Saudi J Kidney Dis Transpl. 2017; 28(2): 253-260. doi: 10.4103/1319-2442.202774
46. Mnif O, Belhadj R, Zerelli L, Helal I, El Younsi F, Abdelmoula J, Khedher A. Variations of troponin T in chronic hemodialysis patients: Study of 52 cases. Tunis Med. 2009; 87(4): 285-288.